Welcome to our dedicated page for Voyager Therapeutics news (Ticker: VYGR), a resource for investors and traders seeking the latest updates and insights on Voyager Therapeutics stock.
Overview
Voyager Therapeutics Inc (VYGR) is a biotechnology company focused on developing innovative gene therapies for severe and debilitating diseases of the central nervous system (CNS). Using advanced AAV gene therapy techniques and its proprietary TRACER™ capsid discovery platform, Voyager is dedicated to overcoming traditional barriers in gene delivery and creating transformative solutions for neurological disorders.
Core Technology and Platform
The company leverages its TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) platform to engineer and optimize novel AAV capsids that are designed to cross the blood-brain barrier with high efficiency. This RNA-based screening enables rapid identification of capsid variants with enhanced CNS tropism and controlled tissue targeting, ensuring robust genetic payload delivery to areas of the brain traditionally hard to reach. The platform underpins both its gene therapy and antibody development programs, reflecting a robust integration of genetic science and neuroscience.
Pipeline and Disease Focus
Voyager Therapeutics maintains an extensive pipeline of programs aimed at addressing several critical CNS diseases. The company is developing gene therapy candidates to target conditions such as Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia. Additionally, Voyager is advancing therapies aimed at modifying the pathological processes in Alzheimer’s disease through tau silencing and anti-tau antibodies. Each candidate is carefully designed to modulate protein expression in the CNS, aiming to slow disease progression and improve patient outcomes.
Research and Development Approach
Emphasizing rigorous process development and production scalability, Voyager invests heavily in vector optimization and sophisticated dosing techniques. The company conducts cross-species preclinical studies to ensure that its TRACER-generated capsids achieve widespread and efficient gene expression while minimizing off-target effects. Its commitment to scientific excellence is reflected in its strategic external collaborations, which not only validate its technology but also extend its reach within the neurogenetic medicines field.
Industry Significance and Competitive Position
Voyager Therapeutics distinguishes itself within the biotechnology landscape through its specialized focus on CNS diseases and its innovative AAV-based gene therapy solutions. By integrating cutting-edge gene editing methodologies with deep neuroscientific insights, the company fills a significant unmet need in neurological drug development. Its collaboration with established industry partners further underscores the scientific reliability, stringent development standards, and translational potential of its candidates. The company’s balanced portfolio and technology-driven approach position it as a critical contributor to the evolution of gene therapies for challenging neurological conditions.
Commitment to Innovation and Patient Impact
At the heart of Voyager Therapeutics’ mission is the goal of modifying the course of devastating neurological diseases. By focusing on durable gene expression attainable through a single administration, the company aims to provide long-lasting therapeutic benefits that can transform the quality of life for patients. Its efforts in process development and clinical standardization continue to set benchmarks within the field, reflecting a commitment to excellence that is both scientifically robust and patient-centered.
This comprehensive approach—encompassing advanced vector engineering, strategic collaborations, and meticulous clinical development—underscores Voyager Therapeutics’ prominence in the realm of neurogenetic medicines and offers a detailed perspective for investors and industry observers alike.
Voyager Therapeutics (VYGR) has presented new preclinical data for its tau-targeting programs in Alzheimer's disease treatment at AD/PD™ 2025. The company's tau silencing gene therapy VY1706 demonstrated significant results in non-human primate studies, showing 44-73% reduction in tau mRNA and 27-55% reduction in tau protein levels after a single intravenous dose, with effects lasting up to three months.
The therapy achieved broad brain distribution while showing 30-fold liver de-targeting compared to wild type AAV9. VY1706 is advancing toward IND filing expected in 2026. Additionally, their anti-tau antibody VY7523 showed selectivity for pathologic tau tangles in preclinical studies. The company is currently conducting a multiple ascending dose trial of VY7523 in early Alzheimer's patients, with initial tau PET imaging data expected in second half of 2026.
Voyager Therapeutics (VYGR) reported its Q4 and full year 2024 financial results, highlighting significant progress in its tau-targeting programs for Alzheimer's disease. The company's tau silencing gene therapy VY1706 showed promising results in NHP studies, with 50-73% reduction in tau mRNA levels across the cerebral cortex. Their anti-tau antibody VY7523 demonstrated positive safety and pharmacokinetic results in Phase 1 trials.
Financial highlights include:
- Q4 2024 collaboration revenue of $6.3M vs $90.1M in Q4 2023
- Full year 2024 revenue of $80M vs $250M in 2023
- Q4 2024 net loss of $34.5M vs net income of $56.4M in Q4 2023
- Cash position of $332.4M as of December 31, 2024
The company expects cash runway into mid-2027 and anticipates several key milestones, including IND filings for GBA1 Parkinson's therapies in 2025 and tau PET imaging data from VY7523 trials in H2 2026.
Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has scheduled its fourth quarter 2024 financial results announcement for March 11, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET the same day.
The webcast will be accessible through the Investors section of Voyager's website at ir.voyagertherapeutics.com. A replay will be available at the same location approximately two hours after the call's completion and will remain accessible for at least 30 days.
Voyager Therapeutics (VYGR) has announced positive topline data from its single ascending dose (SAD) trial of VY7523, an anti-tau antibody designed to inhibit pathological tau spread in Alzheimer's disease. The trial, involving 48 healthy volunteers across six dose cohorts, demonstrated safety, tolerability, and dose-proportional pharmacokinetics.
Key findings include:
- No serious adverse events or infusion reactions reported
- Dose-proportionate increase in serum concentrations
- Cerebrospinal fluid-to-serum ratio of 0.3%, aligning with other approved AD antibodies
The company has initiated a multiple ascending dose (MAD) trial involving 52 patients with early Alzheimer's disease. This study will evaluate safety, tolerability, and VY7523's ability to prevent pathologic tau spread through PET imaging. Initial tau PET imaging data is expected in H2 2026.
Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has announced its participation in two upcoming investor conferences in March 2025.
The company will attend the TD Cowen 45th Annual Health Care Conference in Boston, with a fireside chat scheduled for March 3, 2025, at 1:50 p.m. ET. Additionally, Voyager will participate in the Stifel 2025 Virtual CNS Forum, featuring a fireside chat on March 19, 2025, at 11:00 a.m. ET.
Webcasts of both presentations will be available through the Investors section of Voyager's website at ir.voyagertherapeutics.com. Interested parties can access replays of the webcasts, which will remain archived on the company's website for a minimum of 30 days after the events.
Voyager Therapeutics (VYGR) announced a setback in its SOD1 ALS gene therapy program, as three-month non-human primate data revealed the need to assess alternate payloads for VY9323. The siRNA payload component showed off-target effects, resulting in a narrowed therapeutic window. While the novel capsid component remains unchanged, the company will no longer file its planned IND application in mid-2025.
This development extends the company's cash runway into mid-2027, excluding potential milestone payments from partnerships. Despite this setback, Voyager maintains its timeline for other programs, including expected IND filings in 2025 for GBA1 Parkinson's and Friedreich's ataxia programs, and in 2026 for VY1706 (tau silencing) gene therapy program.
Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has announced its participation in the Oppenheimer 25th Annual Healthcare Life Sciences Conference. The company will engage in a fireside chat scheduled for February 11, 2025, at 2:40 p.m. ET.
The presentation will be accessible via webcast through the Investors section of Voyager's website at ir.voyagertherapeutics.com. Interested parties can access a replay of the webcast, which will remain available on the company's website for a minimum of 30 days following the presentation.
Voyager Therapeutics (VYGR) has selected VY1706 as its lead development candidate for tau silencing gene therapy in Alzheimer's disease. The company plans to file IND and CTA applications in 2026. VY1706 combines siRNA technology to reduce tau expression with an IV-delivered TRACER capsid that can penetrate the blood-brain barrier. In non-human primate studies, a single VY1706 dose achieved 50% to 73% reduction in tau mRNA levels across the cerebral cortex, particularly in areas where tau accumulates during Alzheimer's progression. This marks the fifth neuro gene therapy development candidate using Voyager's TRACER capsids.
Voyager Therapeutics (VYGR) reported Q3 2024 financial results with collaboration revenue of $24.6 million, up from $4.6 million in Q3 2023. Net loss decreased to $9.0 million from $25.9 million year-over-year. The company completed enrollment in its VY7523 anti-tau antibody trial for Alzheimer's, with top-line data expected H1 2025. Voyager secured a new $15 million upfront payment from Novartis for a TRACER capsid license and received a $3 million milestone payment from Neurocrine. Cash position stands at $345.4 million, providing runway into 2027.
Voyager Therapeutics (VYGR) has announced its participation in four upcoming investor conferences in November 2024. The company will be present at the Truist Securities BioPharma Symposium in New York City (Nov 7), the Guggenheim Inaugural Healthcare Innovation Conference in Boston (Nov 13), the B. Riley Securities' Next-Gen Tissue Delivery Modalities Virtual Summit (Nov 14), and the Stifel 2024 Healthcare Conference in New York City (Nov 18).
Webcasts will be available for select conferences and can be accessed through Voyager's investor relations website, with replays available for at least 30 days.
FAQ
What is the current stock price of Voyager Therapeutics (VYGR)?
What is the market cap of Voyager Therapeutics (VYGR)?
What is the primary focus of Voyager Therapeutics?
What is the TRACER™ platform?
Which central nervous system diseases does Voyager address?
How does Voyager’s technology enhance gene delivery to the brain?
What distinguishes Voyager Therapeutics from other biotech companies?
Does Voyager collaborate with other organizations?
How do Voyager's therapies aim to impact patient treatment?
What research methods support Voyager's development approach?
